Delivered-To: tjphuhs@gmail.com Received: by 2002:adf:e74f:0:b0:439:fcfb:30e with SMTP id c15csp947767wrn; Thu, 19 Mar 2026 05:37:00 -0700 (PDT) X-Received: by 2002:a05:6a20:d530:b0:39b:949d:6078 with SMTP id adf61e73a8af0-39b99cbb964mr6431519637.6.1773923820602; Thu, 19 Mar 2026 05:37:00 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1773923820; cv=none; d=google.com; s=arc-20240605; b=gI0KLLV1hMFCjG3Oj0QNk55pN/HTA1La7mPxAALQiq34odZMyoN9YDmN9PrN4nF4vo b9zLCmyBtPPzSdj8eghdcP7pODHOvnkK72rKjnq/YZMHWzaV8aS9aTu5UVamzbIMZTG2 NNuadmo+C5X4xqNdM4wNcUS/HGbl1OSmIDFw6hwwEJoYH+NKRqf1u2Fn5FLnRw5wEKxd IDkjRMIyhnd1DAZkmwp2iyAFSjWveRvrSfkjpsTZoXTyESDBNMqzyWPzpYALkDgt6Vde xXGVnNDtbcKTVohIv0xizVacsMXVCiT4SX8X+wgMkgThmcGnTMNNmS7gE9a4zbxo8OJu PrLA== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=kBmNO2hj5dhpMc2XsWAo1HETi/jqc1dPg5sPPVB9pIY=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=emuR/wbo9oQjJoRYzcz+wmj9bY4OC1UmBOZkc5RrUgb/7si1hd4aan6OzK5GsnwT95 1OpS/43V4hXU9QkKEFxdaYWVbo8tl4JkRfxZhYdC1dBLiQlzewQkV5DRpb2mWTpmOcry icBpBJ1FzMA6jY2wNTY8TEctDe8BK2wit0vLyhvvI8NlH+fZwc6ma+k/v4jYSHIs3KoI bZTzFWJRIxlRBAprvaw5GMEogj2w/6vkmUprgJJWpvzJLDWmsviyyUTieBX9ndMz+7Na jYA8QENpxJsvwOJQvD0psq065exQtvOKcPkD5PfAHgSNltNUpj1FaRX9Oq39F0W6v6kX oVyA==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg2.substack.com header.s=mailo header.b="bKNRcR/g"; dkim=pass header.i=@mailgun.org header.s=mg header.b=V94Kcylb; spf=pass (google.com: domain of bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com designates 161.38.201.120 as permitted sender) smtp.mailfrom="bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v5120.v5075e2e3.usw1.send.mailgun.net (v5120.v5075e2e3.usw1.send.mailgun.net. [161.38.201.120]) by mx.google.com with UTF8SMTPS id 41be03b00d2f7-c741e0eb21dsi11666420a12.116.2026.03.19.05.36.59 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Thu, 19 Mar 2026 05:37:00 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com designates 161.38.201.120 as permitted sender) client-ip=161.38.201.120; Authentication-Results: mx.google.com; dkim=pass header.i=@mg2.substack.com header.s=mailo header.b="bKNRcR/g"; dkim=pass header.i=@mailgun.org header.s=mg header.b=V94Kcylb; spf=pass (google.com: domain of bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com designates 161.38.201.120 as permitted sender) smtp.mailfrom="bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg2.substack.com; q=dns/txt; s=mailo; t=1773923819; x=1773931019; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=kBmNO2hj5dhpMc2XsWAo1HETi/jqc1dPg5sPPVB9pIY=; b=bKNRcR/gtBweTsgfqUsOBmy5BVEjOcDB/jXoXjV3B/j4YjMwgSHC2z0udaG8BezaGEWjotjCKbHHvatb9VI90Rt1npdI5de8oX9HqYFAH1a/D3S44ZuSEJAJgG69t+uQRRafjrCAq+XkNzfH/k/UVYKpx+5kkj3xedFeKFRxq4o= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1773923819; x=1773931019; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=kBmNO2hj5dhpMc2XsWAo1HETi/jqc1dPg5sPPVB9pIY=; b=V94KcylbknPCxumRP16+2hafw/CKGcIUN087Nf7ckRc0f20oh2w5RhTWjPoZO1pgQTSzC/3h8n6Zknq6HhVglNuqAjHYFTM1LTu/qmXdqWotYnCW7HeWMwI9gs0HFWrMOJcfRAPGnNdeSRVXghLTjj6LjnKOkytkgnyplYqKAa4= X-Mailgun-Sid: WyIxODZiYSIsInRqcGh1aHNAZ21haWwuY29tIiwiNGQxODU4Il0= X-Feedback-Id: postmaster@mg2.substack.com:post:5a78b6d5cd16820001f2a9d4:mailgun Received: by d7ddcbbc5ec68f5d97d1b10d793f65d276abc46c6bb9e40d0aed205bb20c99d5 with HTTP id 69bbedeb44ebe00971578df3; Thu, 19 Mar 2026 12:36:59 GMT X-Mailgun-Sending-Ip: 161.38.201.120 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="f7d7428b0f5d433b3374366a11616eb9e7d55e477e45bde278063f7c502a" Subject: =?UTF-8?q?Tesamorelin_Degradation_Data_=E2=80=94_We're_Getting_It_After_A?= =?UTF-8?q?ll_|_Peptide_Crafters_3-Month_Study_|_Month_1_Sneak_Peek?= From: Derek from Peptide Price To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260319123506.3.9b8be225bdde96fe@mg2.substack.com> Date: Thu, 19 Mar 2026 12:35:06 +0000 Feedback-Id: post-191470734:cat-post:pub-3365367:substack Sender: Derek from Peptide Price References: In-Reply-To: Reply-To: Derek from Peptide Price List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1773923819198", "is_freemail": "true", "post_audience": "everyone", "post_id": "191470734", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --f7d7428b0f5d433b3374366a11616eb9e7d55e477e45bde278063f7c502a Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/tesamorelin= -degradation-data-were I know a lot of you were disappointed when our own degradation study throug= h Freedom Diagnostics didn=E2=80=99t work out. The good news is we=E2=80=99= re going to get that data anyway =E2=80=94 Peptide Crafters is running a th= ree-month Tesamorelin degradation study and gave me an early look at the mo= nth one results. The setup is straightforward: two samples from the same batch, one stored a= t room temperature and one refrigerated, tested once a month for three mont= hs. The goal is to compare purity and degradation loss across both storage = conditions over time and give the community real data to work with. By the = time this wraps we=E2=80=99ll have a complete month-by-month picture of wha= t=E2=80=99s actually happening to Tesamorelin under each storage condition. These are the one-month results, tested by Janoshik on March 16, 2026. Two = more months of data still to come. One thing to note upfront =E2=80=94 they only sent me the month one COAs. I= don=E2=80=99t have the baseline purity from day zero, so I can=E2=80=99t g= ive you exact degradation numbers yet. We=E2=80=99ll get the complete pictu= re as the study progresses. Month 1 Results =E2=80=94 Batch PC-G2-TS10 Sample B (Room Temperature, 1 month) =E2=80=94 Tesamorelin: 10.81 mg | Puri= ty: 98.184% Sample C (Refrigerated, 1 month) =E2=80=94 Tesamorelin: 10.59 mg | Purity: = 99.732% Looking at these results, a purity of 99.732% after one month in the fridge= is about as clean as it gets. Even the room temperature sample is sitting = at 98.184% at the one month mark, which is still a strong number. The narrative that keeping Tesamorelin refrigerated somehow causes degradat= ion has floated around this space for too long. One month in, refrigerated = storage is looking exactly like you=E2=80=99d expect =E2=80=94 negligible i= mpact on purity. We=E2=80=99ll see how month two and three shake out, but t= he early data is about what any reasonable person would predict. I=E2=80=99ll share the full results as each month comes in. Stay tuned =E2= =80=94 this is going to be a useful data set for the community. Big shoutout to Peptide Crafters for running this and giving me the early l= ook. More to come. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVNVFEzTURjek5Dd2lhV0YwSWpveE56Y3pPV= El6T0RFNUxDSmxlSEFpT2pFNE1EVTBOVGs0TVRrc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5Li13bDFuZTRZOU1ZNzVtTnZ2dWI5TnRmUkZ= yTy1UMFA5OEpNZWRQM2ZxWGciLCJwIjoxOTE0NzA3MzQsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzczOTIzODE5LCJleHAiOjIwODk0OTk4MTksImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.e1ZMnSpAZH0PZ1LAe7SMxKYXTExVZeQ7ylG6uut= BUok? --f7d7428b0f5d433b3374366a11616eb9e7d55e477e45bde278063f7c502a Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Tesamorelin Degradation = Data — We're Getting It After All | Peptide Crafters 3-Month Study | = Month 1 Sneak Peek3D""
I know a lot of you were disappointed when our own degradation study t= hrough Freedom Diagnostics didn’t work out.
͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­

Tesamorelin Degradation Data — We're Getting It After Al= l | Peptide Crafters 3-Month Study | Month 1 Sneak Peek

Forwarded t= his email? Subscribe here for = more
Derek
 = ;
3D""
= 3D""
3D""
3D""
READ IN A= PP3D""
 

I know a lot of you were disappointed when our own degradation study throu= gh Freedom Diagnostics didn’t work out. The good news is we’re = going to get that data anyway — Peptide Crafters is running a three-m= onth Tesamorelin degradation study and gave me an early look at the month o= ne results.

The setup is straightforward: two samples from = the same batch, one stored at room temperature and one refrigerated, tested= once a month for three months. The goal is to compare purity and degradati= on loss across both storage conditions over time and give the community rea= l data to work with. By the time this wraps we’ll have a complete mon= th-by-month picture of what’s actually happening to Tesamorelin under= each storage condition.

These are the one-month results, t= ested by Janoshik on March 16, 2026. Two more months of data still to come.=

One thing to note upfront — they only sent me the mo= nth one COAs. I don’t have the baseline purity from day zero, so I ca= n’t give you exact degradation numbers yet. We’ll get the compl= ete picture as the study progresses.

Month 1 Results = — Batch PC-G2-TS10

    Sample B (Room Temper= ature, 1 month) — Tesamorelin: 10.81 mg | Purity: 98.184%

    =
    3D"Test
    =

    • Sample C (Refrigerated, 1 month) — Tesamorelin: 10.59 = mg | Purity: 99.732%

    =
    3D"Test

    Looking at these results, a puri= ty of 99.732% after one month in the fridge is about as clean as it gets. E= ven the room temperature sample is sitting at 98.184% at the one month mark= , which is still a strong number.

    The narrative that keepin= g Tesamorelin refrigerated somehow causes degradation has floated around th= is space for too long. One month in, refrigerated storage is looking exactl= y like you’d expect — negligible impact on purity. We’ll = see how month two and three shake out, but the early data is about what any= reasonable person would predict.

    I’ll share the full= results as each month comes in. Stay tuned — this is going to be a u= seful data set for the community.

    Big shoutout to Peptide C= rafters for running this and giving me the early look.

    More= to come.

    Upgrade to paid

<= span class=3D"pencraft pc-reset reset-IxiVJZ" translated=3D"" style=3D"list= -style: none;color: unset;text-decoration: unset;margin: 0;">You're current= ly a free subscriber to Peptid= e Price. For the full experience, upgrade your subscrip= tion.

Upgrade to paid

=
 
 <= td>
3D""Share
 
3D"=Like<= /span>
<= tr><= /tr>
3D""Comment
3D""Restack
 

© 2026 Dere= k Pruski
548 Market Street PMB 72296, San Francisco, CA 94104 Unsubscribe

<= /div>

3D"Start=

3D"" --f7d7428b0f5d433b3374366a11616eb9e7d55e477e45bde278063f7c502a--